product name Mometasone furoate
Description: Mometasone Furoate (also known as SCH-32088) is a glucocorticoid receptor agonist, used topically to reduce inflammation of the skin or in the airways. Like other topical corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti- inflammatory activity of the topical steroids remains unclear.
References: Immunopharmacol Immunotoxicol. 2006;28(3):491-500; Eur J Pharmacol. 2005 Nov 7;524(1-3):155-8.
521.43
Formula
C27H30Cl2O6
CAS No.
83919-23-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 6 mg/mL (11.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
SCH-32088
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422557
| In Vitro |
In vitro activity: Mometasone furoate efficiently suppresses production of cytokines including interleukin (IL)-4, IL-5, and interferon-gamma in anti-CD3-stimulated human CD4+ T cells. Mometasone furoate effectively inhibits the activation of Th cells including type 2 Th (Th2) in the draining LN, thus leading to the suppression of the IgE response. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Mometasone causes a decrease in the instances of nasal rubbing and an inhibition of this response is observed during the treatment period in rats. Mometasone (3 mg/kg) inhibits the increased airway sensitivity to aerosolized methacholine at the highest dose tested in mice. Mometasone, given an hour after the last allergen challenge, dose-dependently inhibits the allergen-induced increase in Penh with about a 10-fold loss of potency when compared with the pre-challenge treatment schedule. Mometasone furoate (0.02%) and fluticasone propionate (0.1%) significantly inhibits the increase of antigen-induced nasal rubbing even 6 hours after topical application, indicating that both drugs have a long-lasting effect. Mometasone furoate dose-dependently inhibits the elevated eosinophil numbers in the bronchoalveolar lavage fluid and lung tissues of sensitized, ovalbumin challenged mice. Mometasone furoate (33 mg/kg) reduces the percentage of CD44+ T-helper cells (activated/memory cells) to the levels observed in non-sensitized, ovalbumin-challenged mice. |
| Animal model | |
| Formulation & Dosage | |
| References | Immunopharmacol Immunotoxicol. 2006;28(3):491-500; Eur J Pharmacol. 2005 Nov 7;524(1-3):155-8. |
